Transforming the NSCLC Treatment Landscape with Antibody Drug Conjugates

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.

Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.